+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 23 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a new bevacizumab drug made by Mabscale, LLC, compared to Avastin, both combined with paclitaxel and carboplatin, for treating adults with advanced or inoperable non-squamous non-small cell lung cancer NSCLC. This phase III trial aims to show that the new bevacizumab works as well and is as safe as Avastin. The study also looks at how the drug is processed in the body. Participants are randomly assigned to one of two groups. One group receives the Mabscale bevacizumab with paclitaxel and carboplatin, and the other gets Avastin with the same chemotherapy drugs. Treatment cycles last about three weeks, with up to six cycles initially. After that, eligible patients continue with bevacizumab alone every three weeks. The study is double-blind, so neither patients nor researchers know who receives which bevacizumab. During the study, patients will undergo regular assessments including tumor measurements and blood tests. Researchers measure the tumor response at 18 weeks and track progression-free and overall survival at 18 and 42 weeks. The duration of response is also evaluated up to 48 weeks. Safety and side effects are closely monitored throughout the trial, which started in 2023 and will continue until 2027. Participants are followed closely to assess the treatments impact and safety.

Age: 18Years +All GendersPhase 3
28 locations
C

Actively Recruiting

Researchers are evaluating the safety and effectiveness of BCD-248 combined with daratumumab compared to a combination of daratumumab, pomalidomide, and dexamethasone for treating adults with relapsed or refractory multiple myeloma. This study focuses on participants aged 18 and older who have measurable multiple myeloma and have received previous treatments including a proteasome inhibitor and lenalidomide, specifically those who are refractory to lenalidomide or have had disease progression after prior therapies. Participants will receive either BCD-248 administered under the skin with daratumumab given intravenously, or the combination of daratumumab intravenously with pomalidomide and dexamethasone taken orally. The study is randomized without masking, comparing these two treatment groups in parallel. The intervention period includes monitoring for up to 36 months to assess disease progression and response, with additional long-term evaluations lasting up to 5 years. During the trial, participants will undergo assessments including measuring minimal residual disease using flow cytometry at 12 months, and monitoring progression-free survival per established criteria. Other evaluations include response rates, survival, immune markers, and adverse events over several years. Safety and treatment effects will be closely followed with regular clinical visits and laboratory tests throughout the study duration, which extends until October 2032.

Age: 18Years +All GendersPhase 3
16 locations
P

Actively Recruiting

Researchers are evaluating etelcalcetide in children with secondary hyperparathyroidism SHPT who also have chronic kidney disease CKD and are receiving hemodialysis. SHPT is a serious condition that develops early in CKD and can cause bone and growth problems as well as increased cardiovascular risks in children on dialysis. This phase 3 trial aims to provide important safety and efficacy data for etelcalcetide in pediatric patients aged 28 days to under 18 years, addressing the limitations of current treatments like vitamin D sterols. Participants are randomly assigned in a 51 ratio to receive either etelcalcetide along with standard care or standard care alone. The standard care may include treatments such as vitamin D sterols, calcium supplements, or phosphate binders. The study involves multiple doses of etelcalcetide, with assessments conducted over weeks to monitor its effects on parathyroid hormone levels and mineral balance. During the study, participants will undergo regular evaluations including blood tests to measure intact parathyroid hormone, calcium, and phosphorus levels. Researchers will also monitor safety by tracking adverse events and changes in vital signs, growth, and development stages. The primary outcome focuses on the percentage of participants achieving a significant reduction in hormone levels over weeks 20 to 27. The trial includes careful monitoring throughout treatment and up to approximately 30 weeks after the last dose.

Age: 0Years - 18YearsAll GendersPhase 3
43 locations
O

Actively Recruiting

Researchers are evaluating the efficacy and safety of BCD-248 as a treatment for patients with relapsed or refractory multiple myeloma, a condition where the disease has returned or is resistant to previous therapies. This open-label phase 2 clinical study aims to assess the overall response rate and other important outcomes in this patient population. The study is sponsored by Biocad and focuses on patients who have received multiple prior treatments including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 therapy. Participants will receive BCD-248 administered subcutaneously. The study monitors various outcomes including overall response rate up to 24 weeks and progression-free survival up to 104 weeks, among others, over a total duration extending to about 3.7 years for some measures. Pharmacokinetic parameters like Cmax, Cmin, AUC0-t, and Ctrough will be tracked shortly after administration and up to 6 months. Additional assessments include measurement of soluble BCMA levels and the presence of binding and neutralizing antibodies. During the study, participants will undergo regular evaluations including disease assessments based on International Myeloma Working Group criteria, safety monitoring for adverse events, and laboratory tests. Long-term follow-up will include evaluation of response duration, time to response and progression, and overall survival. The study started in December 2024 and is expected to continue until July 2028, providing extended observation for participant outcomes and safety.

Age: 18Years +All GendersPhase 2
20 locations
O

Actively Recruiting

Researchers are evaluating the safety, efficacy, and tolerability of sodium zirconium cyclosilicate SZC in children under 18 years old with hyperkalaemia, a condition involving high potassium levels. This phase 3, open-label study involves about 140 participants across roughly 46 sites in Europe, North America, and other locations. It starts with two age cohorts 6 to under 12 years and 12 to under 18 years, with potential expansion to younger cohorts based on data review by an independent monitoring committee. Treatment includes three phases the Correction Phase CP, Maintenance Phase MP, and Long-Term Maintenance Phase LTMP. Participants in CP receive SZC orally three times daily for up to 3 days until potassium levels normalize, with doses adjusted by body weight equivalent to adult doses of 5 g, 10 g, or 15 g. Those achieving normal potassium enter the MP, receiving once-daily SZC for 28 days with dose adjustments to maintain levels. Participants may then continue into the LTMP, following a similar dose regimen with monthly visits. Throughout the study, participants undergo blood tests, ECG monitoring, urine analyses, and safety assessments to track potassium levels, aldosterone, electrolytes, and kidney function. Researchers measure effectiveness by the ability to achieve and maintain normal potassium levels and monitor safety and tolerability in all phases. The study duration is about 28 weeks, including treatment and a safety follow-up one week after the last dose.

Age: 0Years - 18YearsAll GendersPhase 3
70 locations
S

Actively Recruiting

Researchers are evaluating the safety, effectiveness, and pharmacodynamics of a single dose of ANB-002, a gene therapy, in adult men with hemophilia B who have low factor IX FIX activity and no FIX inhibitor. The study aims to show that ANB-002 is not less effective than standard preventive treatment using FIX concentrates. This is an open-label, phase 3 trial sponsored by Biocad. Participants first undergo a non-interventional lead-in period lasting at least six months during which they receive standard FIX preventive treatment. After this, they enter the main interventional period where they receive a single infusion of ANB-002. This main period lasts 18 months, followed by a follow-up period of up to five years after the ANB-002 infusion. During the study, researchers will monitor participants bleeding rates before and after treatment, FIX activity levels, and FIX concentrate use. They will also assess the proportion of subjects not needing FIX prevention, and track various bleeding events including spontaneous bleedings and hemarthrosis. Safety and treatment effects will be evaluated over the long-term follow-up, with study participation lasting up to five years after treatment.

Age: 18Years +MALEPhase 3
14 locations
O

Actively Recruiting

Researchers are studying adult patients with Neurofibromatosis type 1 NF1 in Russia to evaluate clinical and patient-reported outcomes in routine care settings. This observational, open-label, single-arm, multi-center cohort study focuses on adults diagnosed with NF1 and associated plexiform neurofibromas PN. Participants are adults aged 18 years or older with confirmed NF1 and PN diagnosis verified by clinical assessment, ultrasound imaging, MRI, or biopsy. The study includes patients with existing PN-associated symptoms who are either newly diagnosed or have PN without prior MEK-inhibitor therapy. No investigational drugs are given, as this is a non-interventional study observing routine care. During the study, participants provide data at their initial visit, including demographics, clinical history, PN characteristics, comorbidities, disability degree, and prior examinations. Researchers collect information on hospitalizations and disease progression over time. The primary outcomes include age at inclusion and diagnosis, body measurements, symptom duration, and disability changes. Participants are followed according to routine care until study completion in 2028.

All AgesAll Genders
16 locations
O

Actively Recruiting

Researchers are conducting a large observational study involving 5,000 adult patients across about 50 regions in Russia who have uncontrolled severe asthma and are receiving standard treatments except biologic therapies. The study aims to better understand the characteristics, treatment patterns, and clinical outcomes of these patients, as there is currently limited data on this population in Russia. The study will not interfere with routine clinical care and is designed to collect comprehensive real-world information. Participants will have one study visit to gather demographic and clinical data without any additional diagnostic or therapeutic procedures beyond their usual care. This cross-sectional study will take place at 50 outpatient centers experienced in treating uncontrolled severe asthma, enrolling about 100 patients per region. The study will run from June 2024 to June 2027. During the single visit, researchers will collect information such as patients treatment regimens, use of oral corticosteroids, demographic details, clinical characteristics including comorbidities, lung function, and biomarkers like blood eosinophil counts and Immunoglobulin E levels. They will analyze these data to characterize treatment patterns and clinical outcomes in this population. No interventions are given, and patient safety is monitored through standard medical practice.

Age: 18Years +All Genders
40 locations
P

Actively Recruiting

Researchers are evaluating Raphamin in adults aged 18 to 64 years who have acute bronchitis symptoms lasting less than 72 hours. This randomized, double-blind, placebo-controlled phase 3 trial aims to determine if Raphamin can speed up symptom resolution, reduce disease severity, and prevent complications requiring antibiotics compared to placebo. The study includes both men and women during the seasonal period of acute respiratory viral infections. Participants are randomly assigned to receive either Raphamin or a placebo following a specific oral dosing schedule for 5 days. On the first day, participants take 8 tablets of Raphamin or placebo one tablet every 30 minutes for the first 2 hours total of 5 tablets, then one tablet three times spaced evenly throughout the day. From day 2 onwards, one tablet is taken three times daily. The study uses an electronic patient diary to record daily symptoms, and face-to-face visits are scheduled on days 1, 4, and 7, with a phone visit on day 14. Throughout the study, participants undergo physical exams, vital sign monitoring, pulse oximetry, and laboratory tests including blood counts and PCR for respiratory viruses. Symptom severity is assessed by the Bronchitis Severity Scale and the Integrative Medicine Outcome Scale. Quality of life is evaluated using the EQ-5D instrument. Safety is monitored through recording adverse events and any use of antibacterial medications or hospitalizations. The total duration of participation includes treatment and follow-up over 14 days.

Age: 18Years - 64YearsAll GendersPhase 3
33 locations
S

Actively Recruiting

Researchers are conducting a multicenter, double-blind, placebo-controlled, randomized clinical trial to study children aged 3 to 12 years with acute respiratory viral infection ARVI. This trial aims to evaluate the safety and effectiveness of Raphamin in treating ARVI symptoms during the seasonal incidence of the illness. Enrollment starts with children aged 6 to 12 years and may expand to include those aged 3 to 12 years based on interim safety and efficacy results. Participants will be randomly assigned to receive either Raphamin or a placebo. Raphamin is given orally as tablets that dissolve in the mouth, with a specific dosing schedule over five days eight tablets on the first day taken at intervals, then one tablet three times daily on days two through five. The placebo group follows the same dosing regimen using placebo tablets. The treatment period lasts five days, followed by monitoring and follow-up visits. During the study, parents or caregivers will record their childs symptoms and body temperature twice daily in an electronic diary, including any use of fever-reducing medications and changes in health. Children will have several visits with healthcare providers on days 1, 5, and 7, plus a phone visit on day 14 for safety and symptom assessment. Laboratory tests and physical exams will be conducted to monitor progress and safety. The primary outcome is the time until ARVI symptoms resolve within 14 days.

Age: 3Years - 12YearsAll GendersPhase 3
35 locations

1-10 of 23

1